Loading
Nuclidium
Nuclidium is a Swiss company building radioactive medicines around copper instead of the more usual gallium and lutetium: one copper isotope for a scan that finds the cancer, a sister isotope to treat it. Its first programmes are in advanced prostate cancer, neuroendocrine tumours and breast cancer.
Also called: NUCLIDIUMNuclidium AG
Overview
Nuclidium is a clinical-stage radiopharmaceutical company using copper-61 for PET diagnostics and copper-67 for therapy, with offices in Basel (Nuclidium AG) and Munich (Nuclidium (DE) GmbH). It was founded in 2017 by chief executive Leila Jaafar-Thiel, with Gustav von Schulthess as medical adviser and co-founder. Its pipeline lists NU101, which binds PSMA, for metastatic castration-resistant prostate cancer, and NU201, an SSTR2 antagonist, for gastroenteropancreatic and bronchopulmonary neuroendocrine tumours, metastatic breast cancer and other SSTR-positive tumours, each as a 61Cu diagnostic and a 67Cu therapeutic, plus an undisclosed programme. The company reported positive Phase I/II results for a copper-based PET diagnostic in neuroendocrine tumours in October 2025, and in October 2026 announced the first patient imaged in a Phase 2 study of 61Cu-NU101 in metastatic prostate cancer. It closed a CHF 79 million (EUR 84 million) Series B in July 2025 and an extension in May 2026 that brought the round to CHF 105 million. Partnerships named in its news include Guerbet, PharmaLogic and, in October 2026, NorthStar for copper-67 supply.
Headquarters
Basel, CH
Funding
All startupsGrowth stage
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B extension · CHF 26 million extension, bringing the Series B to CHF 105 million in total | 2026 | undisclosed | nuclidium.com |
| Series B · CHF 79 million (EUR 84 million); no USD figure stated | 2025 | undisclosed | nuclidium.com |
| Grant · EIC Accelerator grant of EUR 2.5 million; a second Innosuisse grant, of EUR 800,000, followed in June 2022 | 2022 | undisclosed | nuclidium.com |
| Grant · Innosuisse grant of EUR 1 million | 2020 | undisclosed | nuclidium.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Growth stage
Website
Founded
2017
Notes
- The company news page does not name the Series B lead investors in the text read; its About page shows investor logos including Angelini Ventures, Bayern Kapital, Eurazeo, Kurma, Wellington Partners and NRW Bank. The pipeline page does not give a phase for each programme. Whether its 61Cu-NuriPro imaging agent is the same compound as NU101 was not confirmed, so the two names are not joined here.
Connected
10Similar pages
- CompanyPOINT Biopharma
Shares Somatostatin receptor 2, PSMA, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- PersonJeremie Calais
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- CompanyAntelope Surgical Solutions
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonLouise Emmett
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- CompanyNuclearMediX
Shares Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Somatostatin receptor 2, Neuroendocrine tumours.
- TrialDual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Shares Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Neuroendocrine tumours.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/